Urinary exfoliated tumor single-cell metabolomics technology for establishing a drug resistance monitoring system for bladder cancer with intravesical chemotherapy. (October 2020)

• Record Type: Journal Article
• Authors: Tian, Junjie; Fu, Guanghou; Xu, Zhijie; Chen, Xiaoyi; Sun, Junjie; Jin, Baiye
• Is Part Of: Medical hypotheses. Volume 143(2020)
• Publication Date: 2020-10
• Subjects: Non-muscle invasive bladder cancer -- Urinary exfoliated tumor cells -- Metabolomics -- Single-cell mass spectrometry -- Drug-resistance; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Medicine; Periodicals; 610
• DOI: 10.1016/j.mehy.2020.110100
• Languages: English
• ISSNs: 0306-9877

Abstract

Abstract: Bladder cancer is one of the most common urogenital malignant with a rising incidence rate all over the world. Non-muscle invasive bladder cancer (NMIBC) has the characteristics of high recurrence rate and easy progression after receiving transurethral tumor resection combined with intravesical chemotherapy. The intrinsic or/and acquired drug resistance is mainly causing this poor outcome. The continuing advances in metabolomics and single-cell mass spectrometry have been considered as the key to promoting clinical precision medicine. Urinary exfoliated tumor cells (UETCs) carry the first-hand biological information on the genesis and progression of primary bladder cancer. Therefore, we hypothesized that the establishment of a drug resistance monitoring system for bladder cancer with intravesical chemotherapy based on UETCs single-cell metabolomics technology has a broad application prospect.